Zepbound/Mounjaro & Ozempic/Wegovy: Complete 2026 Guide to Medical Weight Loss
Dr. Richard Lipman M.D.
Board Certified Internal Medicine/Endocrinology
Reviewed and Updated June 4, 2026
The GLP-1 medications, including Ozempic/Wegovy, Mounjaro, and Zepbound, produce potent weight loss as well as numerous other positive benefits. While they act on similar systems in the human body and share the peptide GLP-1, they are not the same drugs Continue reading to discover the differences between these drugs as they relate to losing weight, improving cardiovascular status, reducing sleep apnea and inflammation and reversing liver and kidney disease. A remarkable effect on human metabolic processes not seen in any drug group.
Are Mounjaro and Ozempic in the Same Drug Class?
figure 1: GLP-1 medications including injections for rapid, safe weight loss
Both Zepbound/Mounjaro and Ozempic are in the class of drugs referred to as incretin mimetics. A mimetic is a substance that mimics or copies the actions of another substance. When we ingest nutrients, our digestive system releases incretins into our bloodstream. There are 2 primary incretin hormones – GIP and GLP-1. GIP binds to the GIP receptor, and GLP-1 binds to the GLP-1 receptor. These are called receptor agonists. GIP and GLP-1 stimulate insulin secretion. Incretin mimetics lower blood glucose levels by mimicking the action of natural incretin hormones. Incretins are also vital to the treatment of obesity by regulating glucose homeostasis and maintaining energy balance. Zepbound is the newestFDA-approved version of the tirzepatide, Mounjaro, and they are exactly the same.
Both drugs treat diabetes and are highly effective. They can both help to reduce the incidence of major cardiovascular events, help regulate blood sugar levels, and help you lose weight. Read comparisons in Table 1.
Is Zepbound/Mounjaro More Effective than Ozempic/Wegovy?
Yes, Zepbound/Mounjaro provides greater weight-loss results than Ozempic. Zepbound is the most potent weight reduction agent approved by the FDA; in head-to-head trials, participants lost 25% of their starting weight.
Table 1: Ozempic/Wegovy vs Mounjaro/Zepbound: Weight Loss, Side Effects, Food Noise, Cost, and Maintenance
| Feature | Ozempic / Wegovy Semaglutide: GLP-1 | Mounjaro / Zepbound Tirzepatide: GLP-1 + GIP | Practical Bottom Line |
|---|---|---|---|
| Main use | Ozempic is mainly for type 2 diabetes. Wegovy is the weight-loss version of semaglutide. | Mounjaro is mainly for type 2 diabetes. Zepbound is the weight-loss version of tirzepatide. | For obesity treatment, compare Wegovy vs Zepbound. For diabetes with weight loss, compare Ozempic vs Mounjaro. |
| Expected weight loss | Wegovy 2.4 mg: about 15% average body-weight loss in major obesity trials. | Zepbound: about 16% to 22% average body-weight loss, depending on dose, in major obesity trials. | Zepbound/Mounjaro usually produces more weight loss, especially at higher doses. |
| Food noise / appetite reduction | Strong reduction in hunger, cravings, portion size, and snacking. Many patients feel full earlier. | Often stronger appetite and craving suppression because tirzepatide works on both GLP-1 and GIP pathways. | Zepbound/Mounjaro often wins for food noise, especially in patients with strong hunger or cravings. |
| Onset of action | Appetite reduction may begin in the first 1–2 weeks, but major weight loss usually builds over months as the dose increases. | Appetite reduction may also begin in the first 1–2 weeks. Some patients notice stronger early appetite control. | Both start working early, but the full effect depends on dose escalation and staying on treatment. |
| GI side effects | Common: nausea, constipation, diarrhea, vomiting, reflux, bloating, and abdominal discomfort. | Common: nausea, constipation, diarrhea, vomiting, indigestion, reflux, and abdominal discomfort. | GI effects are common with both. Slow dose increases, smaller meals, hydration, and avoiding fatty meals help. |
| Which has more side effects? | Usually well tolerated, but nausea and constipation are frequent during dose increases. | May cause more GI symptoms in some patients because the weight-loss and appetite effects can be stronger. | The “best” drug is not just the strongest drug. It is the one the patient can tolerate and continue. |
| Glucose control | Excellent glucose lowering in type 2 diabetes. Ozempic also has cardiovascular and kidney-related indications in selected patients. | Very strong glucose lowering in type 2 diabetes, often with greater A1c and weight reduction than older diabetes medicines. | For diabetes plus obesity, Mounjaro may be stronger for weight and glucose, but insurance coverage and patient history matter. |
| Cost | Brand-name semaglutide is expensive without coverage. Ozempic and Wegovy list prices are often around the high hundreds to over $1,000/month, though savings programs may reduce cost. | Brand-name tirzepatide is also expensive. Zepbound list price is commonly around $1,000/month, but self-pay vial/pen programs may be lower for some patients. | The cheapest option depends on insurance, diagnosis, coupons, dose, and whether the patient qualifies for manufacturer programs. |
| Best for active weight loss | Very effective, especially for patients needing 10–15% weight loss or those who tolerate semaglutide well. | Usually the stronger choice when the goal is larger weight loss, stronger appetite control, or loss above 15–20%. | Zepbound/Mounjaro is usually stronger for active weight loss. |
| Best for maintenance | Good maintenance option if the patient is stable, tolerating it, and hunger remains controlled. | Excellent maintenance option for patients who regain quickly, have strong food noise, or needed larger weight loss to reach goal. | For maintenance, the best drug is the lowest effective dose that controls hunger and prevents regain. Tirzepatide may be better for severe food noise; semaglutide may be enough for many stable patients. |
| Who may do better with semaglutide? | Patients who respond well to lower appetite suppression, need moderate weight loss, or already have good insurance coverage for Ozempic/Wegovy. | Not applicable. | Semaglutide is a strong, proven choice and may be easier to continue if tolerated and covered. |
| Who may do better with tirzepatide? | Not applicable. | Patients with severe hunger, strong cravings, diabetes plus obesity, or those who plateaued on semaglutide. | Tirzepatide is often preferred when stronger weight loss and stronger food-noise control are needed. |
Summary: Ozempic/Wegovy and Mounjaro/Zepbound are both powerful once-weekly weight-loss medications. Semaglutide, the ingredient in Ozempic and Wegovy, is a GLP-1 medication with excellent weight-loss and diabetes data. Tirzepatide, the ingredient in Mounjaro and Zepbound, works on both GLP-1 and GIP receptors and usually produces greater weight loss and stronger appetite suppression. For many patients, Zepbound or Mounjaro is stronger for active weight loss, while either medication can work for long-term maintenance if the dose is adjusted to control hunger and prevent regain.
Cost and coverage change frequently. The actual monthly cost depends on insurance, diagnosis, dose, pharmacy, coupons, and manufacturer savings programs.
Zepbound/Mounjaro are the first and only dual GIP/GLP-1 receptor agonists that control both insulin and glucagon secretion. GIP stands for glucose-dependent insulinotropic polypeptide. GLP-1 is glucagon-like peptide-1. In addition, the GIP hormone controls lipids and fat deposition in the body.
What’s the difference between Ozempic/Wegovy and Zepbound/Mounjaro?
How Does Ozempic/Wegovy Work?
Ozempic works by mimicking incretin and stabilizing insulin secretion. This, in turn, helps blood glucose enter the cells to facilitate energy production. The active ingredient semaglutide also contributes to glycemic control by restricting glucagon release and gluconeogenesis (production of blood sugars in the liver). Ozempic is a glucagon-like peptide-1 agonist and mimics the process of incretin GLP-1.
How Do the Tirzepatides Zepbound/Mounjaro Work?
The Tirzepatides, manufactured by Eli Lilly, are GLP-1 receptor agonists and glucose-dependent insulinotropic polypeptide receptor agonists. It works by modulating both insulin and glucagon. Since insulin controls the amount of blood sugar entering cells and glucagon increases blood sugar, they are dual-acting. Increasing energy production makes Mounjaro one of the most valuable diabetes and weight-loss medications. In addition to blood sugar control, it delays gastric emptying which leads to decreased appetite. Also, the GIP hormone has a direct influence on fats and lipids which would positively impact body weight.
To understand the importance of including both GLP-1 and GIP in a weight-loss medication, it’s helpful to review the hormones’ functions. Both hormones are insulinotropic, but they play distinct roles in various tissues and organs, including bone, brain, fat cells, and the pancreas.
In the brain, both are involved in appetite control. Incretins seem to be less physiologically active in obese individuals, even those who are not diabetic. GLP-1 reduces appetite and slows gastric emptying. It may also be beneficial in fat metabolism. As with most biological systems, balance is the key to optimum functioning.
What Is Ozempic FDA Approved For?
Ozempic is FDA-approved to help regulate glucose levels in adults with type 2 diabetes. It is also used to ameliorate the increased risk of cardiovascular events in adults with type 2 diabetes. It must be prescribed by a healthcare provider. When it first came out more than seven years ago, there was great interest in using it for weight loss. However, with newer Tirzepatide and GLP-1, Ozempic has now been delegated to diabetes treatment.
What Is Wegovy Approved For?
Wegovy has received FDA approval for type 2 diabetes and has been approved for weight loss. A healthcare provider must prescribe it. Wegovy can be used for diabetes but primarily now for weight loss.
What are Zepbound and Mounjaro Approved For?
Mounjaro received FDA approval as a medication to treat type 2 diabetes several years ago, Zepbound, the exact same drug with a differnet name was approved in November 2023 for weight loss. They are classified as GIP and GLP-1 receptor agonists.
Which is More Effective for Weight Loss Zepbound/Mounjaro or Ozempic and Wegovy
“Though Mounjaro and Ozempic are both effective weight loss drugs, Mounjaro and Zepbound have been shown in head-to-head trials to be more effective. The most recent SURMOUNT-1 clinical trials included 2,539 participants, with an average starting body weight of 231 pounds. The study duration exceeded 72 weeks.
At the lowest dose of Mounjaro, 5 mg, participants lost 15% of their body weight. At higher doses, 10 mg and 15 mg, participants lost 25% of their body weight. The average weight reduction was 52 lbs. Participants in the placebo group were only able to reduce body weight by 1.3%.
When considering these medications, it is important to assess the effects that weight-loss drugs have on the digestive tract. Gastrointestinal side effects are slightly lower with Mounjaro/zepbound than other medications. It is easier for obese patients to control food intake, maintain compliance, and achieve weight loss goals when they do not have the added stress of feeling ill.
Mounjaro/Zepbound helps people lose weight through the following mechanisms:
- Directly reduces appetite and increases metabolism by action in the brain.
- Reduces glucagon secretion which decreases hunger.
- Causes individuals to eat less carbs and fatty food.
- Increases insulin production, but only when blood sugar is high. That makes the risk of low blood sugar minimal.
- Decreases the liver’s production of sugar and increases the uptake of blood glucose by muscle tissue. This, in turn, will improve glycemic control.
- Slows down the speed at which the stomach empties food into the intestine. Feeling satiated for a longer period will help those with a weight related condition.
- Trizepatides may show less muscle loss especially when combined with exercise.
How long does it take to start losing weight on Zepbound/Mounjaro?
You can start losing weight on these medications in the first week, but more commonly, it takes two to three weeks to see weight loss in most GLP-1s. The medication’s action that leads to weight loss begins shortly after the first injection. Some of our patients achieve noticeable weight loss after just 2-3 weeks, with gains increasing near the 6-week mark. Patients often sustain substantial weight reductions at 28 weeks. This depends on adherence to a standard dosing schedule, proper diet, and adequate energy expenditure. However, patients’ weight-loss results depend on starting weight, recent weight-loss programs, age, race, gender, and various health conditions, including medications.
How much body weight will I lose on Zepbound or Mounjaro?
The average loss in body weight in Mounjaro/zepbound drug trials was 28 lbs., or 25%. Our patients have experienced similar results. A higher dose may produce more significant weight loss but I’ve seen significant weight loss with doses as low as 2.5 mg a week. Weight loss is very individual. It depends not only on the conditions given above and also on some unknown individual characteristics
How long does it take to start losing weight on all 4 GLP-1’s
You can start losing weight on in 1-2 weeks. On average, patients report noticeable weight loss after 3-4 weeks, with further loss at 6-8 weeks. With faster weight loss on Mounjaro and Zepbound versus Ozempic and Wegovy
How much weight will I lose on Ozempic/Wegovy ?
Clinical trials show you can lose 15-20% of your body weight on Ozempic. Many patients report losing an average of 10% of their starting weight after only 8 weeks.[
Zepbounnd/Mounjaro vs Ozempic Cost
Ozempic & Wegovy Cost
Wegovy is FDA approved for weight loss. However, insurance coverage varies. Some insurance company determinations depend on your starting weight, your endocrine system condition, or whether you have high blood pressure or are at risk for heart disease. The average monthly retail price for Wegovy is $ 1,100. Marked reductions are available with coupons at Novo’s Pharmacy in Orlando and online. New prices can range from $149 to $350 for Wegovy GO, available as oral pills and injections.
Zepboun/Mounjaro Cost from New Lilly Direct for online cash customers
Zepbound, was first listed for more than $1,000 when it was released several years ago just approved for weight loss will be listed at about $1000/month. Mounjaro retails for approximately $1200 per month. Eli Lilly does have some coupons available.
A year after release, the prices have fallen dramatically. With a coupon, which is not hard to get, you can buy the Mounjaro and Zepbound injectable pens for approximately $500 a month. Interesting, all the doses cost the same. Currently, you can buy Zepbound vials from Lilly Direct. For approximately $450 a month. Recently. We introduced a multi-dose pen similar to the Ozempic pen at even a slightly lower cost. We have sent hundreds of patients to Lilly Direct to buy the vials, and almost 100% have been pleased with the service and product.
Are the doses of Zepbound/Mounjaro and Ozempic the same?
The doses of Mounjaro and Ozempic are not the same. Zepbound and Mounjaro dosing ranges from 2.5mg to 15mg, while Ozempic dosing ranges from 0.25mg to 2.4mg.
Zepbound/Mounjaro Dosage–Microdosing.
To reduce the risk of severe allergic reactions or serious side effects, the starting dose is 2.5 mg. A dose is taken once weekly. Doses are increased each week as follows: 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The maximum recommended dose is 15 mg. The weekly subcutaneous injection can be given in the upper arm, thigh, or stomach. Injection sites should be rotated each week. People have taken lower doses to avoid side effects, a practice called microdosing, and have had great success. Dr. Lipman has over 400 patients taking microdoses, with starting doses of 1.25 mg or less for Mounjaro and Zepbound. For these doses, the vials from Lilly Direct are the easiest and most accurate to use.
Ozempic dosage
Ozempic treatment begins with a dosage of 0.25mg per week for 4 weeks. Just as with other drugs, the dosage schedule for Mounjaro and Ozempic can vary according to the needs of each patient. All patients taking GLP-1 drugs need to be monitored by a medical professional who will analyze their current medical condition and their family history. The injections follow a weekly dosing schedule as they are gradually increased to the maximum dose of 2.4mg .
What are the side effects of GLP-1 medications, including Zepbound/Mounjaro, Ozempic/Wegovy?
Side effects of Zepbound and Mounjaro are similar to Ozempic/Wegovy and can include the following:
- GI side effects including nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain
- Low blood sugar
- Allergic reactions
- Gallbladder problems
- Blurred vision
- Kidney problems
- High blood pressure
- Possible thyroid tumors or thyroid cancer*
*In animal studies, thyroid cancer (thyroid tumors) has developed with the use of Mounjaro and Ozempic. Mounjaro is contraindicated if you or any family member have had medullary thyroid carcinoma.
The most common side effects of Ozempic are similar to Mounjaro’s side effects. In addition, lower blood sugar levels could occur; symptoms include confusion, hunger, fatigue, and irritability. Though kidney problems can occur, kidney failure is rare. The most common side effects of both medications are nausea, constipation/diarrhea, upset stomach, and indigestion.